Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;16(4):264-273.
doi: 10.1177/20514158211059057. Epub 2021 Dec 1.

Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways

Artitaya Lophatananon  1 , Alexander Light  2   3 , Nicholas Burns-Cox  4 , Angus Maccormick  4 , Joseph John  5 , Vanessa Otti  5 , John McGrath  5 , Pete Archer  6 , Jonathan Anning  7 , Stuart McCracken  8 , Toby Page  9 , Ken Muir  1 , Vincent J Gnanapragasam  2   3   10
Affiliations

Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways

Artitaya Lophatananon et al. J Clin Urol. 2023 Jul.

Abstract

Introduction: Modern image-guided biopsy pathways at diagnostic centres have greatly refined the investigations of men referred with suspected prostate cancer. However, the referral criteria from primary care are still based on historical prostate-specific antigen (PSA) cut-offs and age-referenced thresholds. Here, we tested whether better contemporary pathways and biopsy methods had improved the predictive utility value of PSA referral thresholds.

Methods: PSA referral thresholds, age-referenced ranges and PSA density (PSAd) were assessed for positive predictive value (PPV) in detection of clinically significant prostate cancer (csPCa - histological ⩾ Grade Group 2). Data were analysed from men referred to three diagnostics centres who used multi-parametric magnetic resonance imaging (mpMRI)-guided prostate biopsies for disease characterisation. Findings were validated in a separate multicentre cohort. Results: Data from 2767 men were included in this study. The median age, PSA and PSAd were 66.4 years, 7.3 ng/mL and 0.1 ng/mL2, respectively. Biopsy detected csPCa was found in 38.7%. The overall area under the curve (AUC) for PSA was 0.68 which is similar to historical performance. A PSA threshold of ⩾ 3 ng/mL had a PPV of 40.3%, but this was age dependent (PPV: 24.8%, 32.7% and 56.8% in men 50-59 years, 60-69 years and ⩾ 70 years, respectively). Different PSA cut-offs and age-reference ranges failed to demonstrate better performance. PSAd demonstrated improved AUC (0.78 vs 0.68, p < 0.0001) and improved PPV compared to PSA. A PSAd of ⩾ 0.10 had a PPV of 48.2% and similar negative predictive value (NPV) to PSA ⩾ 3 ng/mL and out-performed PSA age-reference ranges. This improved performance was recapitulated in a separate multi-centre cohort (n = 541).

Conclusion: The introduction of MRI-based image-guided biopsy pathways does not appear to have altered PSA diagnostic test characteristics to positively detect csPCa. We find no added value to PSA age-referenced ranges, while PSAd offers better PPV and the potential for a single clinically useful threshold (⩾0.10) for all age groups.

Level of evidence: IV.

Keywords: MRI; PSA; PSA density; Prostate cancer; diagnosis; predictive value.

PubMed Disclaimer

Conflict of interest statement

Conflicting interests The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

References

    1. Taitt HE. Global trends and prostate cancer: A review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018;12(6):1807–1823. - PMC - PubMed
    1. National Institute for Health and Care Excellence. Prostate cancer: Diagnosis and management. NICE guideline [NG131]; 2019. [accessed 25 March 2021]. https://www.nice.org.uk/guidance/ng131 . - PubMed
    1. Davies C, Castle JT, Stalbow K, et al. Prostate mpMRI in the UK: The state of the nation. Clin Radiol. 2019;74(11):894.e11–894.e18. - PubMed
    1. Sokhi HK, Padhani AR, Patel S, et al. Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice. Clin Radiol. 2020;75(12):950–956. - PubMed
    1. Van der Leest M, Cornël E, Israel B, et al. Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naïve men with elevated prostate-specific antigen: A large prospective multicenter clinical study. Eur Urol. 2019;75(4):570–578. - PubMed